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Abstract  
Objective 
To review the evidence for the efficacy and safety of colchicine in children with pericarditis.  
 
Design 
Systematic review 
 
Search strategy 
The following databases were searched for studies about colchicine in children with pericarditis 
(June 2015): Cochrane Central, Medline, EMBASE and LILACS.  
 
Eligibility criteria 
All observational and experimental studies on humans with any length of follow-up and no 
limitations on language or publication status were included. The outcomes studied were 
recurrences of pericarditis and adverse events. 
 
Data extraction 
Two authors extracted data and assessed quality of included studies using the Cochrane risk of 
bias tool for non-randomized trials. 
 
Results 
Two case series and nine case reports reported the use of colchicine in a total of 86 children with 
pericarditis. Five articles including 74 paediatric patients were in favour of colchicine in 
preventing further pericarditis recurrences. Six studies including 12 patients showed that 
colchicine did not prevent recurrences of pericarditis.  
 
Limitations 
No randomised controlled trials were found. 
 
Conclusion 
Although colchicine is an established treatment for pericarditis in adults, it is not routinely used 
in children. There is not enough evidence to support or discourage the use of colchicine in 
children with pericarditis. Further research in the form of large double-blind randomised 
controlled trials is needed to establish the efficacy of colchicine in children with pericarditis. 
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INTRODUCTION 
Pericarditis is the inflammation of the pericardium, the membranous sac surrounding the heart. 
Pericarditis is idiopathic in 80% of cases, however it is presumed to be viral in origin 1. Other 
causes of pericarditis include post-pericardiotomy syndrome, tuberculosis or bacterial and 
neoplastic diseases 2. Post-pericardiotomy syndrome is a more common cause in children than in 
adults 3. 
 
The incidence of pericarditis is 2-3 in every 1000 hospitalised children 4. Symptoms include 
chest pain and fever which can present as recurrent episodes in up to 15% - 30%. Recurrent 
pericarditis severely impairs quality of life and can be disabling5. 
 
The diagnosis of pericarditis can be challenging. The most common signs include a pericardial 
rub or effusion1 and electrocardiography (ECG) changes such a widespread ST-segment 
elevation might be present. Raised inflammatory markers such as erythrocyte sedimentation rate 
(ESR) or C-reactive protein (CRP) with chest pain might be the only signs1.  
 
Colchicine has been shown to be effective in preventing recurrent episodes in adults 6–9, however 
it is not routinely used in children 10. The objective of this systematic review was to identify the 
efficacy and safety of colchicine in children. 
METHODS 
This systematic review was registered in the international database of prospectively registered 
systematic reviews in health and social care (PROSPERO) on the 20th July 2015 (registration 
number: CRD42015024647) 11. 
 
Data Sources 
The following databases were searched (from their start to June 2015): Cochrane Central, 
Medline, EMBASE and LILACS. The search did not include any language or time restriction. 
The search strategy was designed for maximum sensitivity using the Boolean operator AND to 
combine all synonyms for colchicine with all possible ways of referring to pericarditis. (See 
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appendix 1 for full details.) In addition, bibliographic references of identified articles were 
reviewed. We searched www.clinicaltrials.gov for on-going trials on 14th February 2016. 
 
Eligibility Criteria 
Although randomised controlled trials (RCT) are the best way to test treatments, we anticipated 
that we would not find many. Therefore our eligibility criteria were any study design of 
pericarditis in children treated with colchicine. There was no limitation on length of follow-up, 
language or publication status. 
 
Outcomes 
1) Efficacy of colchicine in treating children with pericarditis, defined as prevention of 
recurrences or symptom relief. 
2) Adverse effects and tolerability of colchicine in children. 
 
Data extraction and analysis 
Two authors independently screened titles and abstracts for inclusion. The opinion of a third 
author was sought when an agreement could not be reached. Full-text publications were obtained 
for included studies or where eligibility was unclear from the title and abstract. Two authors 
extracted data and assessed quality of included studies using a pre-defined data collection form.  
We adopted the Cochrane risk of bias tool for non-randomized trials (ACROBAT-NRSI) to 
assess the quality of included studies 12. The tool assesses domains of confounding, selection of 
participants, outcome measurement, missing data and follow-up. 
 
Subgroup analysis 
We planned to analyse dose regimens used and duration of treatment.  
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RESULTS 
A total of 352 records were identified. Removal of duplicates left 266 articles for screening. A 
total of 68 full texts were assessed for eligibility and 11 articles met the inclusion criteria 
(Figure 1). No additonal study was found through the manual search of bibliographic references 
of the retrieved papers. No ongoing clinical trials were found on clinicaltrials.gov. 
Figure 1 Study Flow Diagram 
 
Study Characteristics 
Two case series 13,14 and nine case reports 4,15–19 reported the use of colchicine in a total of 86 
children with pericarditis.  Studies reported children with different severities of pericarditis. 
Three studies (two case reports and one case series) were in children with post-pericardiotomy 
syndrome 13,20,21.  The study characteristics are given in table 1.  
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Quality of included studies 
1) Selection of participants  
Two case series were included. Consecutive inclusion of patients was reported in one of the 
studies 14, while we could not tell if all consecutively patients were included in the other case 
series 13.  
2) Risk of bias of confounding. 
No included study pre-specified a list of potential confounders of pericarditis therapy. No study 
carried out statistical modelling for confounding factors or adjusted for time-varying 
confounding. 
We could not tell from the included reports if confounding factors such as indication of 
treatment, additional therapies, type of pericarditis and age of children, affected the effect of 
colchicine. 
3) Outcome measurement and assessment 
Methods for collecting data were poorly reported and we could not tell if any of the studies 
used more than one outcome assessor to repeat the analysis to ensure reliability. 
None of the included studies had control groups. Findings were reported as recurrence free 
period after colchicine. Two studies reported pre- and post- colchicine recurrence rate 13,14.  
4) Missing data 
The included papers did not report incomplete or missing data. We could not tell if this because 
of lack or reporting or absence of missing data. However, the included case reports had 
appropriate follow up of 6 – 24 months (Table 1).  
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Study 
Type 
Children 
on 
Colchicine 
Type of 
Pericarditis 
Age 
(years) 
Gender 
Follow 
up 
(months) 
Colchicine 
Dose 
Response to 
colchicine 
Adler 1998 Case 
report 
1 Idiopathic  2  female 6  
1 mg/day 
for 6 
months 
No 
recurrences 
Blasco 
2006 
Case 
report 
1 
Post‐
pericardiotomy  12  male 24  1 mg/day 
Further 
recurrences 
Brucato 
2000 
Case 
report 
1 Idiopathic  14  male 29  
1 mg/day 
for 6 
months 
No 
recurrences 
Brucato 
2013 
Case 
series 
67 
87% idiopathic 
and 9% post‐
pericardiotomy  
13 
(range 1 
‐ 17) 
62% 
male 
60 (6 ‐
360) 
0.5‐ 1.5 
mg/day  
Reduced 
Recurrences 
Del Fresno 
2013 
Case 
reports 
2 
Post‐ 
pericardiotomy  4  
male 
and 
female 
24  
0.5mg/day 
for 4 
months 
Further 
recurrences 
Jurko 2002 Case 
reports 
2 Idiopathic  not 
reported 
not 
reported 
9 and 12  not 
reported 
No 
recurrences 
Peterlana 
2005 
Case 
report 
1 Idiopathic  11  male 60 1 mg/day  
Further 
recurrences 
Picco 2009 Case 
reports 
3 Idiopathic  12, 13 
and 14  
1 male, 
2 female 6  
1 mg/day 
for 6 
months 
Further 
recurrences 
Raatikka 
2003 
Case‐
series 
4 
Post‐
pericardiotomy  
8, 9, 12 
and 15  
3 males, 
1 female 
96p (48 ‐ 
192) 
0.5‐ 2 
mg/day for 
6 months 
Further 
recurrences 
Scardapane 
2012 
Case 
report 
1 Idiopathic  11  male 24  
1 mg/day 
for 6 
months 
Further 
recurrences 
Yazigi 1998 
 
Case 
reports 
3 Idiopathic  4, 5 and 
14  male 17 ‐ 24  
0.25 ‐ 0.5 
mg/day for 
6 months 
No 
recurrences 
 
Table 1 Study Characteristics 
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Two articles were only available as conference abstracts 14,17 which limited the amount of data 
available.  
 
Efficacy of colchicine or pericarditis in children 
Included studies were heterogeneous in populations, study designs and outcome reporting; we 
therefore did not pool data in a meta-analysis. The findings of the included studies are described 
below. Two types of pericarditis were studied: idiopathic pericarditis and post-pericardiotomy 
syndrome.  
 
A detailed data extraction of all included studies is given in Appendix 2. 
 
Idiopathic Pericarditis 
Seven case reports 4,15–19,22 and one case series 14 reported the use of colchicine in children with 
idiopathic pericarditis. 
 
The case reports included 12 children with a median age of 11.5 (range 2-14) and 70% male 
gender distribution. All children had multiple recurrences of pericarditis while treated with 
NSAIDs and steroids. When colchicine was added, 7 out of 12 children (58%) had no further 
recurrences, while the other 5 (42%) continued to have recurrences. The median follow up was 
12 months (range 6 – 60). The included articles did not report the exact number of pericarditis 
recurrences pre and post colchicine treatment. 
 
The case series was only available as an abstract and included 100 children with a median age of 
13 (range 1 – 17) and 62% male gender distribution. Colchicine was added to NSAIDs or 
steroids in 67 patients (67%). The median follow up was 60 months (range 6 – 360 months). The 
number of pericarditis recurrences per year was 3.8 before colchicine was given and 1.6 
afterwards. 
 
Post-pericardiotomy syndrome 
One case series 13 and two case reports 20,21 reported the use of colchicine in children with post-
pericardiotomy syndrome. 
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The case series studied 15 children with at least two recurrences of pericarditis post open heart 
surgery. Four patients were treated with NSAIDs and eleven with steroids. Colchicine was added 
to four patients on steroid treatment. The four patients on colchicine had a median age of 12.5 
years (range 8 to 16 years). All children treated with colchicine had further recurrences of 
pericarditis. The mean number of recurrence while on steroids only was 2.4 recurrences per year 
and increased to 4.8 recurrences per year after colchicine was started. The mean number of 
recurrences in the NSAIDs group were 1.2 recurrences per year. The authors concluded that 
colchicine was not effective in preventing pericarditis recurrences. However, colchicine was only 
used in the more severe steroid-resistant group. 
 
The two case reports included 3 children, one girl aged 4 and two boys aged 4 and 12. The 
children had recurrent episodes of pericarditis following cardiac surgery. The pericarditis 
episodes were not controlled with NSAIDs or steroids.  The three children continued to have 
recurrences during their 24 months follow up after colchicine was added. 
 
Adverse effects of colchicine in children 
Severe adverse events were not reported in the included studies. Adverse effects included   
abdominal symptoms such as nausea and diarrhoea 4,17,23.  
 
Colchicine dose and treatment regime 
Yaazigi 1998 and Del Fresno 2013 used a colchicine dose of 0.25 - 0.5 mg/day for 4 - 6 months. 
Colchicine 1 mg/day was used by (Adler 1998, Brucato 2000, Scardapane 2012 and Picco 2014, 
Peterlana 2005, Blasco 2006) for 6 months.  Scardapane 2012 and Brucato 2013 used 1mg - 1.5 
mg/day. Brucato 2013 also used 0.5mg / day for children less than 5 years. Raatika 2003 used a 
colchicine dose of up to 2 mg/day. 
DISCUSSION 
Colchicine is an established treatment for pericarditis in adults 6–9. It’s efficacy to reduces 
recurrences and help relieving symptoms has been proven in a number of RCTs 24–29. However, 
no RCT has been carried out in children 30 and there are no ongoing trials. We estimate that a 
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RCT with 82 children is needed to detect the same pericarditis recurrence risk reduction as in 
adults (for 5% significance level and 80% power). 
 
This systematic review shows that the evidence on colchicine in children is scarce, of poor 
quality and contradictory. The largest case series from 2013 14 has still not been published as a 
full text. One case series 14 and four case-reports 4,15–17 including 74 children were in favour of 
using colchicine to prevent further pericarditis recurrences. These children had mainly an 
idiopathic pericarditis. On the other hand, one case series 13 and five case reports 18–22 including 
12 children showed that colchicine did not prevent recurrences. Three of these studies were in 
children with post-pericardiotomy syndrome 13,20,21 . Two  studies 18,19 reported children with 
pericarditis resistant to colchicine but responded to the use of interleukin-1b receptor antagonist 
(anakinra).  
Studies reported that colchicine was well tolerated in children although the small number of 
included children might not be representative. It is noted that colchicine is not licensed in either 
the USA or Europe for the use in pericarditis31.  
LIMITATIONS 
Very little is reported on the use of colchicine in children in the medical literature. Included 
studies are case series and case reports only, therefore the conclusions of this review are based 
on low quality evidence. Two articles were only available as abstracts 14,17. 
Nine of the twelve included studies were reported from centres in the Mediterranean region 
(Italy, Spain, Lebanon and Israel) 4,14–16,18–22. This is similar to the situation in adult studies 
where all randomized controlled trials of colchicine in pericarditis were done in Italy 31.  It is 
possible that the findings may not apply to groups from other climates or geographical locations. 
Two studies reported pre- and post- colchicine recurrence rate to report colchicine efficacy in 
preventing recurrences 13,14. However, this conclusion is not appropriate as there was no control 
group and it was not possible to tell what the recurrence rate in the same population would have 
been without colchicine.  
CONCLUSIONS 
The available literature suggests that colchicine might be effective in preventing recurrences in 
children with idiopathic pericarditis, however the quality of evidence is very low.  
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Taking into account that colchicine is cheap to produce and effective in adults, it is important 
that its efficacy in children with pericarditis is tested further in the form of large double-blind 
randomised controlled trials. 
 
"What is already known on this topic" 
Two in every thousand hospitalized children experience episodes of pericarditis. Recurrent 
episodes can occur in up to 30% of the affected children, severely impairing their quality of life. 
Colchicine has been shown to be effective in adults. 
 
"What this study adds" 
There is need for large double-blind randomised controlled trials is needed to establish the 
efficacy of colchicine in children with pericarditis   
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Appendix 1 
Search Strategy 
 CENTRAL 
 
#1 MeSH descriptor: [Pericarditis] explode all trees 
 
#2 MeSH descriptor: [Pericardium] this term only 
 
#3 pericard* 
 
#4 #1 or #2 or #3 
 
#5 MeSH descriptor: [Colchicine] explode all trees 
 
#6 colchi* 
 
#7 colchysat or colcine or colcrys or colgout or goutichine or goutnil or kolkicin or "nsc 757" or 
 
tolchicine 
 
#8 #5 or #6 or #7 
 
#9 #4 and #8 
 
 
OVID (MEDLINE and EMBASE) 
1. exp Pericarditis/ 
 
2. Pericardium/ 
 
3. pericard*.tw. 
 
4. or/1-3 
 
5. exp Colchicine/ 
 
6. colchicin*.tw. 
 
7. colchin.tw. 
 
8. colchicum*.tw. 
 
9. colchily.tw. 
 
10. colchimedio.tw. 
 11. colchiquim.tw. 
 
12. colchisol.tw. 
 
13. colchysat.tw. 
 
14. colcine.tw. 
 
15. colcrys.tw. 
 
16. colgout.tw. 
 
17. goutichine.tw. 
 
18. goutnil.tw. 
 
19. kolkicin.tw. 
 
20. nsc 757.tw. 
 
21. tolchicine.tw. 
 
22. colchichin*.tw. 
 
23. or/5-22  
 
24. 4 and 23 
 
 
Appendix 2 
 
Data Extraction of included studies 
Idiopathic pericarditis 
Adler 199815 described a 26 year old man and a 2-year-old girl with idiopathic pericarditis and 
large pericardial effusions. The girl did not respond to non-steroidal anti-inflammatory drugs 
(NSAID), corticosteroids or pericardiocentesis. She was then given colchicine (1 mg/day) for 6 
months. Response to colchicine was described as immediate and dramatic with the resolving of 
the pericardial effusion. No recurrences of pericarditis were observed in a 6 month follow up 
period.  
Yazigi 1998
4
 included 3 children aged 4, 6 and 14 years with multiple recurrent pericarditis and 
pericardial effusion. They did not respond to NSAIDs (salicylates or diclofenac). In addition, 
prednisone was tried in one patient and pericardiocentesis in two patients. However, 
pericarditis recurrences occurred and the patients were then started on colchicine. Colchicine 
was given 0.25 - 0.5 mg/d for 6 months and follow up continued for 12 to 18 months after 
colchicine was stopped. No pericarditis relapses occurred throughout the treatment or follow-up 
period. 
Brucato 2000
16
 describes a 14 year old boy who experienced multiple remittent–intermittent 
recurrences of pericarditis and pleural effusion despite being treated with indomethacin and 
methylprednisolone. He was then started on colchicine 1 mg/day for one year and had no 
further pericarditis recurrences for the follow up period of 29 months. No adverse effects of 
colchicine were noted. 
Jurko 2002
17
_ENREF_6 is an abstract of a study which included 2 children with a severe form 
of idiopathic recurrent pericarditis. Both were dependent on corticosteroids and one became 
cushingoid. Both then received colchicine instead of a steroid and did not have any further 
relapses during a follow up period of 12 months.  
Peterlana 2005
22
 describes four patients with pericarditis. One of the patients was an 11 year 
old boy with pericarditis that was only responsive to high dose (50mg) prednisone. On attempts 
to reduce the dose of prednisone to 15-20mg he experienced multiple (15) recurrences of 
pericarditis. To reduce the steroid dose, colchicine 1 mg/day was added, however without 
effect. The same patient did not respond to other medications such as methotrexate, 
cyclosporine, azathioprine or intra-venous immunoglobulin (IVIG). The authors concluded that 
colchicine was ineffective in preventing recurrences in resistant pericarditis and suggested 
using IVIG in such cases. 
Picco 2009
18
 reports 3 children aged 12, 13 and 14 years with recurrent pericarditis and pleural 
effusions. These patients represent all consecutive cases of recurrent idiopathic pericarditis 
between 2005 and 2008. The patients were treated with high dose prednisone (1 - 2 mg/kg/day) 
with or without NSAIDs. In addition, one patient had a pericardiotomy and another 
pericardiocentesis.  Pericarditis recurrences occurred once prednisone dose was tapered down 
to (0.5 mg/kg/day). All three patients were started on colchicine 1 mg/day in a bid to reduce 
steroid dose. The patients developed further pericarditis episodes within 2 months of starting 
colchicine and had further recurrences later. The patients’ symptoms eventually settled after 
starting interleukin-1b receptor antagonist (anakinra). However, they had recurrences of 
pericarditis soon after anakinra was discontinued. No adverse effects of colchicine were 
reported.  
Scardapane 2012
19
 reports an 11 year old boy with recurrent episodes of pericarditis and 
pericardial effusion. He was initially treated with ibuprofen (35 mg/kg/day) and prednisone (1 
mg/kg/day). Three months later a further pericarditis episode required hospitalisation and 
colchicine (1 mg/day) was added to ibuprofen and the tapering steroid. The boy was symptom 
free for 20 months while on colchicine. The steroid was tapered down to 0.15 mg/kg/day after 
which the boy had a further pericarditis recurrence. Colchicine dose was increased to 1.5 
mg/day and ibuprofen was substituted with indomethacin (2 mg/kg/day), while continuing on 
prednisone 0.15 mg/kg/day. After a 6 months recurrence free period, the boy was readmitted 
with a new recurrence. Colchicine and indomethacin were stopped and anakinra was given after 
which symptoms resolved and the patient had no further recurrences for 12 months. No adverse 
effects of colchicine were reported. The authors concluded that anakinra is an effective 
alternative to colchicine and NSAIDs or for those who experience adverse effects with steroids.  
Brucato 2013
14
 is an abstract of a retrospective case series of 100 consecutive cases of children 
with pericarditis recruited from 7 centres in Italy. All included children had at least two 
recurrences of pericarditis prior to recruitment. The aetiology of pericarditis was 88% 
idiopathic and 10% post-pericardiotomy and 2% familial Mediterranean fever. The mean age of 
included patients was 13 (range 1 – 17) with a 62% male gender distribution.  
Colchicine (0.5mg – 1.5mg) was added to NSAIDs or steroids in 67 patients (67%). The 
participants were followed up for a median of 73 months (range 3 – 312 months). The included 
patients had on average 1.6 pericarditis recurrences / year compared to 3.8 recurrences / year 
before colchicine was started. Based on the reduction of the number of pericarditis recurrences 
before and after taking colchicine, the authors concluded that colchicine halved the number of 
recurrences in their study population. 
 
Post-pericardiotomy syndrome 
Raatikka 200313 studied 15 children with recurrent pericarditis post open heart surgery. Patients 
were included if they had at least two recurrences of pericarditis after the initial attack. Four 
patients were treated with NSAIDs and eleven with steroids. Four patients had further 
recurrences despite steroid treatment and were given colchicine. The four patients on colchicine 
were aged 7 to 17 years. Colchicine dose given was 0.5- 2 mg/day and follow-up was for 4 - 16 
years (mean 8 years). All children treated with colchicine had further recurrences of pericarditis. 
The number of recurrences while on steroids plus colchicine ranged from 3 – 10 recurrences 
(mean 5.8) during a follow up period of 6 - 27 months (mean 13.3 months). The number of 
recurrences while on steroids only and before colchicine was started was 4 - 15 recurrences 
(mean 7.5) during a follow up period of 10 to 71 months (mean 35 months). This equates to a 
mean of 0.4 recurrences/month with colchicine and a mean of 0.2 recurrences/month before 
colchicine. The total mean of recurrences of pericarditis in patients who were treated with 
steroids (with or without colchicine) was 8.3 and ranged from 2 to 26 recurrences during a 
follow-up of 48 months or 0.17 recurrences/month. The mean recurrences of pericarditis in the 
NSAIDs group was 4.6 (range 2 to 6) or 0.1 recurrences/month. Total remission over 4 years was 
reported in 5 (45%) of the patients treated with steroids and 2 (50%) of the patients treated with 
NSAIDs. The authors concluded that colchicine was not effective in preventing pericarditis 
recurrences. Colchicine was only used in the more severe steroid-resistant group, therefore we 
could not compare it to the steroid or NSAID responsive group.  
Blasco 2006
20
 reports a 12 year old boy who developed a recurrent episodes of pericarditis 2 
months post-cardiac surgery (atrial septal defect closure). The patient was started on NSAIDs 
and improved. NSAIDs were stopped after two months. Two weeks later the patient had 
recurrence of his symptoms. He was restarted on NSAIDs with additional colchicine (1 
mg/day) and had a rapid resolution of symptoms. Two months later, the patient had another 
relapse when the NSAID dose was tapered while still on colchicine. NSAID dose was increased 
again and treatment with NSAID and colchicine continued for another 6 months and then 
stopped. One month after stopping treatment he had another recurrence of pericarditis. 
Treatment with NSAID and colchicine was restarted. NSAID was given for 2 months and 
colchicine continued until his follow-up.  . On follow up, 10 months later, he remained 
symptom free while still being treated with colchicine. The authors concluded that post-
pericardiotomy pericarditis showed a partial response to colchicine. No adverse effects of 
colchicine are reported. 
Del Fresno 2013
21
 reports two 4 year-old children with recurrent pericarditis due to post-
pericardiotomy syndrome. The first patient was a girl who had corrective surgery for tetralogy 
of Fallot. She developed pericarditis and pleural effusion that initially responded to prednisone 
(2 mg/kg/day). Prednisone was tapered down and eventually stopped after 11 weeks and the 
patient developed a recurrent episode of pericarditis and pleural effusion three weeks 
afterwards. Prednisone 1 mg/kg/day was restarted and in addition to colchicine 0.5mg/day for 4 
months. The patient did not improve and developed pericardial effusions. Her symptoms were 
controlled after adding IVIG to her therapy. She remained recurrence free for 13 months 
afterwards. 
The second patient was a boy who had cardiac surgery for hypertrophic obstructive 
cardiomyopathy. After surgery he developed pericarditis and pleural effusion. He was treated 
with ibuprofen, prednisone 2mg/kg/day and colchicine 0.75 mg/day for 2 years. His pleural 
effusion worsened three months later and methotrexate and IVIG were added to control his 
pericarditis and pericardial effusion.  
The authors concluded that colchicine was not effective in resistant pericarditis and suggested 
IVIG as alternative therapy. 
 
